TickerGuard
Buy Day today: Good (67) Broad market participation · no major macro event

Fulgent Genetics Inc (FLGT)

Healthcare Diagnostics & Research
17.60 $
+6.4% vs. previous close
Closing price · As of: 3. Aug 2026

Who owns Fulgent Genetics Inc (FLGT)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 58.8% of the shares are freely tradable; institutional investors hold 63.5%.

Ownership Structure

Institutional ownership
63.5%
Insiders
36.7%
Float
58.8%
Short % of float
15.3%
Shares Outstanding
28Mio.

Largest Shareholders

Institutions

Institutions FLGT
Name Stake (%) Shares Change (%) Date
BlackRock Inc 10.08 2,774,519 -6.3 03/31/2026
RTW INVESTMENTS, LLC 4.68 1,289,000 +82.8 03/31/2026
Acadian Asset Management LLC 4.48 1,233,951 +1,481.4 03/31/2026
Vanguard Capital Management, LLC 3.20 880,150 +0.0 03/31/2026
Dimensional Fund Advisors, Inc. 2.44 671,664 -24.4 03/31/2026
Invenomic Capital Management, LP 2.22 610,318 +0.0 03/31/2026
Geode Capital Management, LLC 2.12 584,207 +15.0 03/31/2026
Ameriprise Financial Inc 2.05 563,375 +12.8 03/31/2026
State Street Corp 1.92 529,399 +7.2 03/31/2026

Funds

Funds FLGT
Name Stake (%) Shares Change (%) Date
Vanguard Morn Total Stk Mkt Idx Investor 2.01 551,839 -11.7 06/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Insider Transactions

Insider Transactions
Date Person Role Type Shares Price Value
26. Jul 2026 Kim Paul CFO and Treasurer Other 2,747 19.67 54,033
26. Jul 2026 Xie Jian President and COO Other 4,361 19.67 85,781
26. Jul 2026 Gao Hanlin Chief Scientific Officer Other 1,645 19.67 32,357

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.

View all insider transactions →

Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?